Biogen Korea, the Korean branch of the American multinational biotech Biogen, said Monday it selected Hwang Se-eun as its new CEO.
Hwang is expected to drive the growth of the company with her experience in the domestic and overseas pharmaceutical market, the company said.
Having graduated from Chung-Ang University College of Pharmacy and obtaining her masters at Sogang Business School, Hwang has worked at various pharmaceutical companies such as JW Pharmaceutical, MSD Korea, Abbott Korea, and Handok.
“I feel a great sense of duty and responsibility as the CEO of Biogen Korea, which provides innovative treatment options and continually thinks about diseases with a high unmet medical demand,” Hwang said. “Biogen Korea will work to achieve growth by securing a firm place in the domestic healthcare market.”
Biogen Korea established its Korean branch in July, having created Samsung Bioepis as a joint venture with Samsung BioLogics in 2012.
“Biogen Korea will concentrate all its capabilities to become a trustworthy partner by creating an environment where more patients will be able to get treated quickly,” Hwang said.
<© Korea Biomedical Review, All rights reserved.>